John M. Stewart, Ph.D.

Publications

398 papers (20 in last 3 years), 23 patents and 321 abstracts total. These are a sampling.

A new generation of bradykinin antagonists. J.M. Stewart, L. Gera, W. Hanson, J.S. Zuzack, M. Burkard, R. McCullough and E.T. Whalley. Immunopharmacology 33: 52-60, 1996.

Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors. M. Burkard, J.S. Zuzack, S. Jones, M. Francis, E.T. Whalley, J.M. Stewart and L. Gera. Immunopharmacology 33: 186-190, 1996.

In vivo pharmacological profile of novel, potent, stable BK antagonists at B1 and B2 receptors. W.L. Hanson, R.G. McCullough, W.M. Selig, M. Weiczorek, S. Ross, E.T. Whalley, J.M. Stewart and L. Gera. Immunopharmacology 33: 191-193, 1996.

An NMR, CD, molecular dynamics and fluorometric study of the conformation of bradykinin antagonists B9340, B9430, B9436 and B9452 in water and in aqueous micellar solutions. J. Sejbal, J.R. Cann, J.M. Stewart, L. Gera and G. Kotovych. Immunopharmacology 33: 198-200, 1996.

Novel bradykinin antagonist dimers for the treatment of human lung cancers. D. Chan, L. Gera, B. Helfrich, K. Helm, J. Stewart, E. Whalley and P. Bunn. Immunopharmacology 33: 201-204, 1996.

Helix propensities of basic amino acids increase with the length of the side-chain. S. Padmanabhan, E.J. York, J.M. Stewart and R.L. Baldwin. J. Mol. Biol. 257: 726-734, 1996.

Potent, long-acting, orally-active bradykinin antagonists for a wide range of applications. J.M. Stewart, L. Gera, D.C. Chan, E.T. Whalley, W.L. Hanson and J.S. Zuzack. Immunopharmacology 36: 167-172, 1997.

Bradykinin antagonists in human systems: Correlation between receptor binding, calcium signalling in isolated cells, and functional activity in isolated ileum. M. Wieczorek, A. Pilyavskaya, M. Burkard, J.S. Zuzack, S.W. Jones, M.D. Francis, V.E. Beckey, S.E. Ross, V.S. Goodfellow, T.D. Fitzpatrick, M.V. Marathe, A. Gyorkos, L.W. Spruce, W.M. Selig, J.M. Stewart, L. Gera and E.T. Whalley. Biochem. Pharmacol. 54: 283-291, 1997.

Oral activity of peptide bradykinin antagonists following intragastric administration in the rat. E.T. Whalley, W.L. Hanson, J.M. Stewart and L. Gera. Can. J. Physiol. Pharmacol. 75: 629-632, 1997.

New classes of bradykinin antagonists having anti-cancer and/or antiinflammatory activity. L. Gera, J.M. Stewart, D. Chan, E.T. Whalley, J.S. Zuzack and M.R. Burkard, in "Peptides 1996", R. Ramage and R. Epton, Eds. Mayflower Scientific Ltd., Kingswinford, U. K., 1998, pp. 415-416.

Potent, wide-spectrum, orally-active bradykinin antagonists. J.M. Stewart, L. Gera, E.T. Whalley, W.L. Hanson and J.S. Zuzack, in "Peptides 1996", R. Ramage and R. Epton, Eds. Mayflower Scientific Ltd., Kingswinford, U. K., 1998, pp. 815-816.

Dimers of bradykinin and substance P antagonists as potential anti-cancer drugs. J.M. Stewart, L. Gera and D.C. Chan, in "Peptide Science - Present and Future", Y. Shimonishi, Ed. Kluwer, Dordrecht, 1998, pp. 754-755.

Des-Arg9-BK antagonists. J.M. Stewart, E.T. Whalley and L. Gera. U. S. Patent 5,834,431, 10 Nov 1998.

Cytolytic bradykinin antagonists. E.T. Whalley, J.M. Stewart, D.C. Chan and L. Gera. U. S. Patent 5,849,863, 15 Dec 1998.

Novel highly-potent bradykinin antagonists containing pentafluorophenylalanine. L. Gera and J.M. Stewart, in "Peptides: Frontiers of Peptide Science", J.P. Tam and P.T.P. Kaumaya, Eds. Kluwer, Dordrecht, 1999, 730-732.

NMR and CD conformational studies of bradykinin and its agonists and antagonists: Application to receptor binding. G. Kotovych, J.R. Cann, J.M. Stewart and H. Yamamoto. Biochem. Cell Biol. 76: 257-266, 1998.

An NMR conformational analysis of a synthetic peptide Cn2(1-15)NH2-S-S-Acetyl-Cn2(52-66)NH2 from the New World Centruroides noxius 2 (Cn2) scorpion toxin. H. Yamato, J. Sejbal, E. York, J.M. Stewart, L.D. Possani and G. Kotovych. Biopolymers 49: 277-286, 1999.

Bradykinin and substance P antagonists as potential anti-cancer drugs. J.M. Stewart, D.C. Chan, L. Gera and E.J. York, in "Peptides 1998", S. Bajusz and F. Hudecz, Eds. Akademiai Kiado, Budapest, 1999, 54-55.

Dimers of bradykinin antagonists and their smaller molecular mimetics as potential anti-cancer drugs. L. Gera, D.C. Chan, B. Helfrich, P.A. Bunn, Jr., E.J. York and J.M. Stewart, in "Peptides 1998", S. Bajusz and F. Hudecz, Eds. Akademiai Kiado, Budapest, 1999, 850-851.

Cyclic and linear bradykinin analogs: implications for B2 antagonist design. K.H. Hsieh and J.M. Stewart. J. Peptide Res. 54: 23-31, 1999.

Bradykinin antagonists containing pentafluorophenylalanine. J.M. Stewart and L. Gera. U.S. Patent 5,935,932, 10 August 1999.

Mapping an epitope recognized by a neutralizing monoclonal antibody specific to toxin Cn2 from the scopion Centruroides noxius, using discontinuous synthetic peptides. E. S. Calderon-Aranda, B. Selisko, E. J. York, G. B. Gurrola, J. M. Stewart and L. D. Possani. Eur. J. Biochem. 264: 746-755, 1999.

Bradykinin antagonists: Present progress and future prospects. J. M. Stewart, L. Gera, E. J. York, D. C. Chan and P. Bunn. Immunopharmacol. 43: 155-161, 1999.

Potentiation of the vascular response to kinins by inhibition of myocardial kininases. A. Dendorfer, S. Wolfrum, U. Schafer, J. M. Stewart, N. Inamura and P. Dominiak. Hypertension 35: 32-37, 2000.

Structure-activity relationships for bradykinin antagonists on the inhibition of cytokine release and the release of histamine. S. Reissmann, F. Pineda, G. Vietinghoff, H. Werner, L. Gera, J. M. Stewart and I. Paegelow. Peptides 21: 527-533, 2000.

An NMR conformational analysis of cyclic bradykinin mimics. Evidence for a b-turn. M. Miskolzie, H. Yamamoto, E.J. York, J.M. Stewart and G. Kotovych. J. Biomol. Struct. Dynamics 17: 947-955, 2000.

Importance of the N-terminal b-turn in bradykinin antagonists. M. Miskolzie, L. Gera, J.M. Stewart and G. Kotovych. J. Biomol. Struct. Dynamics 18: 249-260, 2000.

Non-competitive pharmacological antagonism at the rabbit B-1 receptor. J.F. Larrivee, L. Gera, S. Houle, J. Bouthillier, D.R. Bachvarov, J.M. Stewart and F. Marceau. Brit. J. Pharmacol. 131: 885-892, 2000.

Potent bradykinin antagonists having medical potential. J.M. Stewart, L. Gera, E.J. York and D.C. Chan. In "Peptides, Biology and Chemistry" (Proc. 6th Chinese Peptide Symp.), X.-Y. Hu, R. Wang and J.P. Tam, Eds, Kluwer, Dordrecht, 2000, pp 77-80.

Metabolism-resistant bradykinin antagonists: development and applications. J.M. Stewart, L. Gera, E.J. York, D.C. Chan, E.J. Whalley, P.A. Bunn, Jr., and R.J. Vavrek. Biol. Chem. 382: 37-41, 2001.

Structural modifications of highly potent bradykinin antagonists and their pharmacological consequences. J.M. Stewart, L. Gera, E.J. York, D.C. Chan and P.A. Bunn, Jr., in "Peptides 2000" J. Martinez and J.-A. Fehrentz, Eds., EDK, Paris, France, 2001, pp. 945-946.

Bradykinin-related compounds having anti-cancer activity in vivo superior to Cisplatin and SU5416. L. Gera, D.C. Chan, B. Helfrich, P.A. Bunn, Jr., E.J. York and J.M. Stewart, in "Peptides 2000", J. Martinez ad J.-A. Fehrentz, Eds, EDK, Paris, France, 2001, pp 637-638.

Development of lead structures for bradykinin antagonists. S. Reissmann, F. Pineda, C. Schumann, I. Paegelow and J.M. Stewart, in "Peptides 2000", J. Martinez. And J.-A. Fehrentz, Eds, EDK, Paris, France, 2001, pp. 117-118.

Oxytocin antagonists containing novel conformationally constrained amino acids in position two. K. Bakos, L. Gera, J.M. Stewart, J. Havass, G. Falkay and G.K. Toth, in "Peptides 2000" J. Martinez and J.-A. Fehrentz, Eds, EDK, Paris, France, 2001, pp. 579-580.

Bradykinin antagonist decreases early disruption of the blood-spinal cord barrier after spinal cord injury in mice. W. Pan, A.J. Kastin, L. Gera and J.M. Stewart. Neurosci. Lett. 307: 25-28, 2001.